

ForPatients

by Roche

Prostate Cancer

Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Coralie in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy

Trial Status
Completed

Trial Runs In
9 Countries

Trial Identifier
NCT01485861 2011-004126-10
GO27983

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This multicenter, international, Phase Ib/II trial consists of three stages: a Phase Ib, open-label stage in which the recommended Phase II dose was determined for ipatasertib administered in combination with abiraterone and of apitolisib administered in combination with abiraterone (this phase is no longer active), a Phase II, 3-arm, double-blind, randomized comparison of ipatasertib with abiraterone and prednisone/prednisolone versus placebo with abiraterone and prednisone/prednisolone and a safety single-arm, open-label cohort of ipatasertib 400 mg daily alone or in combination with prednisone/prednisolone or prednisone/prednisolone plus abiraterone.

Genentech, Inc.
Sponsor

Phase 1/Phase 2
Phase

NCT01485861 2011-004126-10 GO27983
Trial Identifiers

Eligibility Criteria:

Gender
Male

Age
≥18 Years

Healthy Volunteers
No
